Wet age-related macular degeneration
Diabetic macular edema
Macular edema following retinal vein occlusion
†Wet AMD: On average, people gained 5 letters at 1 month after their first treatment and gained and maintained 6 letters over 1 year on an eye chart with VABYSMO, similar to aflibercept 2 mg. DME: On average, people gained 6 letters at 1 month after their first treatment and gained and maintained 11 letters over 1 year on an eye chart with VABYSMO, similar to aflibercept 2 mg. RVO: On average, people with CRVO gained 13 letters at 1 month after their first treatment while people with BRVO gained 11 letters at 1 month after their first treatment on an eye chart with VABYSMO, similar to aflibercept 2 mg. On average, people with CRVO and BRVO gained and maintained 17 letters over 6 months on an eye chart with VABYSMO, similar to aflibercept 2 mg.
‡VABYSMO is thought to block the VEGF and Ang-2 proteins. The benefit of blocking Ang-2 has yet to be established.
Ang-2=angiopoietin-2; BRVO=branch retinal vein occlusion; CRVO=central retinal vein occlusion; VEGF=vascular endothelial growth factor.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.